Abstract 1375
Background
PD-L1 can predict benefit from anti-PD-1/L1 therapies; TMB is an emerging biomarker that may have additional predictive utility. We compared the utility of high TMB and PD-L1 to predict outcomes in NSCLC non-squamous pts treated with anti-PD-L1 (durvalumab) and anti-CTLA-4 monoclonal antibodies (tremelimumab, D+T).
Methods
NCT02000947 was a ph 1b study in advanced NSCLC; this exploratory study focused on a cohort of IO-naive non-squamous NSCLC who progressed after 1 prior platinum-based therapy. Pts were treated with D 20 mg/kg Q4W up to 12 months and T 1 mg/kg Q4W with the first 4 cycles of D. By 20 OCT 2017, 214 pts received D+T. DNA sequencing was conducted with the FoundationOne CDxTM on 106 tumors and IHC was performed on tumoral PD-L1 on 193 biopsies using the validated SP263 Ventana assay, all of sufficient quality. NSCLC with ≥25% tumor cells stained for PD-L1 at any intensity were PD-L1+ and high TMB was the top tertile of nonsynonymous mutations per Mb (11.41). KM, Cox PH models and Spearman’s rho were calculated; RECIST v1.1 was used for response.
Results
Of 200 biopsies evaluated for TMB, 106 (53%) provided usable data. PD-L1 was modestly correlated with TMB (r = 0.3, p = 0.002). PD-L1+ pts had higher ORR, PFS and OS compared to PD-L1-. TMB high pts had higher PFS than TMB low. HRs for PD-L1+ and TMB high were similar. TMB high/PD-L1+ pts did not have substantially better ORR than single positive pts, and TMB low/PD-L1- had the lowest response.Table: 65PD
| # Pts (# events [PFS]) | ORR % (95% CI) | Median PFS, mo (95% CI) | PFS HR (95% CI); p | |
|---|---|---|---|---|
| TMB high | 37 (27) | 29.7% | 7.1 (1.7,9.1) | 0.60 (0.38,0.96); 0.032 |
| TMB low | 69 (59) | 10.1% | 1.7 (1.6,3.6) | |
| PD-L1+ | 57 (39) | 35.1% | 7.1 (3.5,9.2) | 0.55 (0.38,0.80); 0.0018 |
| PD-L1- | 136 (114) | 11.8% | 3.3 (1.7,3.6) |
Conclusions
The predictive utility of TMB was similar to that of PD-L1 in this cohort of NSCLC pts treated with D+T. This abstract was withdrawn from ASCO.
Clinical trial identification
NCT02000947.
Legal entity responsible for the study
Medimmune LLC.
Funding
Medimmune LLC.
Editorial Acknowledgement
Disclosure
B.W. Higgs, C.A. Morehouse, P.Z. Brohawn, S. Sridhar, R. Raja, G. Gao, J. Englert, K. Ranade: Employment: Medimmune/AstraZeneca; Stock ownership: AstraZeneca.
Resources from the same session
3819 - Could plasma EBV DNA kinetics predict long-term disease-free survival in metastatic nasopharyngeal carcinoma?
Presenter: LIU guoying
Session: Poster Discussion session - Translational research 2
Resources:
Abstract
5658 - Predictive and Pharmacodynamic Biomarkers Associated with Phase II, selective and orally bioavailable AXL Inhibitor Bemcentinib Across Multiple Clinical Trials
Presenter: Bob Holt
Session: Poster Discussion session - Translational research 2
Resources:
Abstract
1120 - Identification and Validation of a 23-Gene Expression Signature for Subtype Classification of Medulloblastoma
Presenter: Qinghua Xu
Session: Poster Discussion session - Translational research 2
Resources:
Abstract
2122 - Phase I Study of CC-90011 in Patients With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin Lymphoma (R/R NHL)
Presenter: Antoine Hollebecque
Session: Poster Discussion session - Translational research 2
Resources:
Abstract
Slides
5050 - Lack of efficiency of Precision Oncology with target-based investigational treatments for patients in Early Phase clinical trials based on pre-screened molecular alterations
Presenter: Bernard Doger de Spéville
Session: Poster Discussion session - Translational research 2
Resources:
Abstract
Poster Discussion session - Translational research 2 - Invited Discussant 62PD, 63PD, 64PD, 1832PD and 1833PD
Presenter: Giampaolo Tortora
Session: Poster Discussion session - Translational research 2
Resources:
Slides
Webcast
4144 - Genomic profile and T cell receptor repertoire of lung adenosquamous carcinomas
Presenter: Gen Lin
Session: Poster Discussion session - Translational research 2
Resources:
Abstract
3857 - Comparative molecular analysis between microsatellite instability-high (MSI-H) tumors with high tumor mutational burden (TMB-H) versus MSI-H tumors with TMB-intermediate/low
Presenter: Mohamed Salem
Session: Poster Discussion session - Translational research 2
Resources:
Abstract
1969 - Representative Sequencing: profiling extreme tumor diversity
Presenter: Kevin Litchfield
Session: Poster Discussion session - Translational research 2
Resources:
Abstract
2302 - Characterization through whole exome sequencing of individuals presenting extreme phenotypes of high and low risk to develop tobacco-induced non-small lung cancer (NSCLC)
Presenter: Jose Luis Perez Gracia
Session: Poster Discussion session - Translational research 2
Resources:
Abstract